Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the…
Nektar Therapeutics chief R&D officer sells $48,048 in stock By Investing.com Nektar Therapeutics chief R&D officer sells $48,048 in stock…
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates Nektar (NKTR) delivered earnings and revenue surprises of -19.05% and 36.26%, respectively, for the quarter ended June 2024. Do the…
Nektar Therapeutics executive sells over $12k in shares By Investing.com Nektar Therapeutics executive sells over $12k in shares…
Earnings call: Nektar Therapeutics unveils drug development progress By Investing.com Earnings call: Nektar Therapeutics unveils drug development progress…
Nektar Therapeutics secures $30 million in private financing By Investing.com Nektar Therapeutics secures $30 million in private financing…